NCT06389591View on ClinicalTrials.gov

RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2027

Conditions
Recurrent Glioblastoma
Interventions
BIOLOGICAL

pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)

pp65 RNA loaded lipid particles or pp65 RNA-LPs administered intravenously

BIOLOGICAL

RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)

personalized tumor mRNA, pp65 fl LAMP mRNA and DOTAP liposomes or RNA loaded lipid particles, RNA-LPs administered intravenously

Trial Locations (1)

32608

RECRUITING

UF Health, Gainesville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Florida

OTHER